13F Holdings
中文EN

WVE Wave Life Sciences, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1631574 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-72.6%
TTM EPS YoY-64.6%
Revenue 3-yr CAGR-6.0%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-320.9%
Net margin-296.9%
FCF margin-293.8%
EBITDA margin-316.1%

Returns

ROE-80.0%
ROA-56.2%
ROIC (approx.)-270.5%
Asset turnover0.19x

Leverage & solvency

Liabilities / assets20.9%
Debt / equity0.00x
Current ratio8.38x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.98x
Accruals ratio-0.9%
Payout ratio—
Capex / revenue1.9%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$42.73M$108.30M$113.31M$3.65M$40.96M
R&D expense$182.78M$159.68M$130.01M$115.86M$121.88M
SG&A expense$75.33M$59.02M$51.29M$50.51M$46.10M
Operating income-$215.38M-$110.40M-$68.00M-$162.72M-$127.02M
Pretax income-$204.38M-$97.01M-$58.19M-$161.14M-$122.45M
Income tax$0$0-$677,000$681,000-$204,000
Net income-$204.38M-$97.01M-$57.51M-$161.82M-$122.25M
EBITDA-$211.94M-$106.51M-$63.00M-$156.15M-$119.53M
EPS (basic)-1.21-0.70-0.54-2.05-2.36
EPS (diluted)-1.21-0.70-0.54-2.05-2.36
Weighted avg. shares (diluted)168.65M138.28M106.10M78.86M51.83M
Balance sheet
Cash & equivalents$602.07M$302.08M$200.35M$88.50M$150.56M
Short-term investments$0————
Receivables$1.28M$1.42M$21.09M——
Current assets$614.81M$320.39M$235.37M$98.54M$162.56M
PP&E, net$7.41M$10.13M$13.08M$17.28M$22.27M
Total assets$638.50M$352.21M$274.95M$146.39M$207.01M
Current liabilities$95.06M$110.95M$186.44M$71.52M$64.20M
Total liabilities$112.27M$134.82M$227.44M$183.60M$166.63M
Shareholders' equity$518.36M$209.51M$39.63M-$45.09M$32.50M
Shares outstanding0153.04M119.16M86.92M59.84M
Cash flow statement
Operating cash flow-$187.49M-$151.03M-$19.43M-$127.78M-$88.99M
Capital expenditure$718,000$938,000$1.11M$1.36M$560,000
Free cash flow-$188.21M-$151.96M-$20.55M-$129.14M-$89.55M
Investing cash flow-$718,000-$938,000-$1.11M-$1.25M-$560,000
Financing cash flow$488.24M$253.89M$132.53M$67.19M$55.83M
Depreciation & amortization$3.44M$3.90M$5.00M$6.57M$7.48M
Stock-based compensation$24.97M$13.14M$9.79M$17.19M$16.41M

Free plan shows the latest 5 periods; Pro shows all 13 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.